Top

Published in:

Open Access 01-12-2022 | Antibiotic | Research

Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions

Authors: Christian Pallares, Cristhian Hernández-Gómez, Tobías Manuel Appel, Kevin Escandón, Sergio Reyes, Soraya Salcedo, Lorena Matta, Ernesto Martínez, Sara Cobo, Laura Mora, Adriana Marín, Adriana Correa, Elsa De La Cadena, Jesús Rodríguez-Baño, María Virginia Villegas

Published in: BMC Infectious Diseases | Issue 1/2022

Abstract

Background

Antimicrobial stewardship programs (ASPs) have become a fundamental pillar in optimizing antimicrobial usage, improving patient care, and reducing antimicrobial resistance (AMR). Herein we evaluated the impact of an ASP on antimicrobial consumption and AMR in Colombia.

Methods

We designed a retrospective observational study and measured trends in antibiotic consumption and AMR before and after the implementation of an ASP using interrupted time series analysis over a 4-year period (24 months before and 24 months after ASP implementation).

Results

ASPs were implemented according to the available resources in each of the institutions. Before ASP implementation, there was a trend toward an increase in the antibiotic consumption of all measured antimicrobials selected. Afterward, an overall decrease in antibiotic consumption was observed. The use of ertapenem and meropenem decreased in hospital wards, while a decrease in the use of ceftriaxone, cefepime, piperacillin/tazobactam, meropenem, and vancomycin was observed in intensive care units. After ASP implementation, the trend toward an increase of oxacillin-resistant Staphylococcus aureus, ceftriaxone-resistant Escherichia coli, and meropenem-resistant Pseudomonas aeruginosa was reversed.

Conclusions

In our study, we showed that ASPs are a key strategy in tackling the emerging threat of AMR and have a positive impact on antibiotic consumption and resistance.

Price L, Gozdzielewska L, Young M, Smith F, MacDonald J, McParland J, et al. Effectiveness of interventions to improve the public’s antimicrobial resistance awareness and behaviours associated with prudent use of antimicrobials: a systematic review. J Antimicrob Chemother. 2018;73(6):1464–78. https://doi.org/10.1093/jac/dky076.CrossRefPubMed

File TM, Srinivasan A, Bartlett JG. Antimicrobial stewardship: importance for patient and public health. Clin Infect Dis. 2014;59(S3):S93–6. https://doi.org/10.1093/cid/ciu543.CrossRefPubMed

O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. May 2016. https://amr-review.org/Publications.html. Accessed 1 Dec 2021.

Allcock S, Young EH, Holmes M, Gurdasani D, Dougan G, Sandhu MS, et al. Antimicrobial resistance in human populations: challenges and opportunities. Glob Heal Epidemiol Genomics. 2017;2:e4. https://doi.org/10.1017/gheg.2017.4.CrossRef

Glaser RJ. General principles of antibiotic therapy. J Am Dent Assoc. 1953;46(2):129–34. https://doi.org/10.14219/jada.archive.1953.0022.CrossRefPubMed

McGowan JE, Gerding DN. Does antibiotic restriction prevent resistance? New Horiz. 1996;4(3):370–6.PubMed

Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98. https://doi.org/10.1016/S1473-3099(13)70318-9.CrossRefPubMed

Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis. 2017;17(2):e56-63. https://doi.org/10.1016/S1473-3099(16)30386-3.CrossRefPubMed

Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas MV, et al. Antibiotic stewardship in low- and middle-income countries: the same but different? Clin Microbiol Infect. 2017;23(11):812–8. https://doi.org/10.1016/j.cmi.2017.07.010.CrossRefPubMed

10.

Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital in patients. Cochrane Database Syst Rev. 2017;2017(2):CD003543. https://doi.org/10.1002/14651858.CD003543.pub4.CrossRefPubMedCentral

11.

Leuthner KD, Doern GV. Antimicrobial stewardship programs. J Clin Microbiol. 2013;51(12):3916–20. https://doi.org/10.1128/JCM.01751-13.CrossRefPubMedPubMedCentral

12.

Feinstein M, Escandón-Vargas K, Reyes S, Hernández-Gómez C, Pallares CJ, Villegas MV. Improved outcomes when antibiotic prescribing guidelines are followed by healthcare providers: a Colombian example to encourage adherence in hospital settings. Infect Control Hosp Epidemiol. 2017;38(06):756–8. https://doi.org/10.1017/ice.2017.45.CrossRefPubMed

13.

Emberger J, Tassone D, Stevens MP, Markley JD. The current state of antimicrobial stewardship: challenges, successes, and future directions. Curr Infect Dis Rep. 2018;20(9):31. https://doi.org/10.1007/s11908-018-0637-6.CrossRefPubMed

14.

Levy HG. Antimicrobial stewardship in hospitals: does it work and can we do it? J Glob Antimicrob Resist. 2014;2(1):1–6. https://doi.org/10.1016/j.jgar.2013.08.001.CrossRef

15.

Pallares CJ, Martínez E. Implementation of a regulated antibiotic use program in two medical-surgical intensive units care in a third level mayor teaching hospital in Colombia. Infectio. 2012;16(4):192–8.CrossRef

16.

Pallares CJ, Cataño JC. Impact of rational use of antibiotics in a third level clinic in Colombia. Rev Chilena Infectol. 2017;34(3):205–11. https://doi.org/10.4067/S0716-10182017000300001.CrossRefPubMed

17.

Fica A, Valenzuela C, Leiva I, Vergara T, Soto A, Dabanch J, et al. Long-term impact of competitive biddings and an antimicrobial stewardship program in a general hospital in Chile. Rev Med Chil. 2018;146(9):968–77. https://doi.org/10.4067/s0034-98872018000900968.CrossRefPubMed

18.

Magedanz L, Silliprandi EM, dos Santos RP. Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study. Int J Clin Pharm. 2012;34(2):290–4. https://doi.org/10.1007/s11096-012-9621-7.CrossRefPubMed

19.

Étienne P, Roger P-M, Brofferio P, Labate C, Blanc V, Tiger F, et al. Antimicrobial stewardship program and quality of antibiotic prescriptions. Médecine Mal Infect. 2011;41(11):608–12. https://doi.org/10.1016/j.medmal.2011.07.010.CrossRef

20.

Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x.CrossRefPubMed

21.

Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16(2):159–77. https://doi.org/10.1517/14656566.2015.993381.CrossRefPubMed

22.

Perozziello A, Routelous C, Charani E, Truel A, Birgand G, Yazdanpanah Y, et al. Experiences and perspectives of implementing antimicrobial stewardship in five French hospitals: a qualitative study. Int J Antimicrob Agents. 2018;51(6):829–35. https://doi.org/10.1016/j.ijantimicag.2018.01.002.CrossRefPubMed

23.

Müller M, Lehmann P, Willy C. Antibiotic stewardship: a programmatic approach to improved antimicrobial management. Unfallchirurg. 2017;120(7):540–8. https://doi.org/10.1007/s00113-017-0365-7.CrossRefPubMed

24.

Goff DA, File TM. The evolving role of antimicrobial stewardship in management of multidrug resistant infections. Infect Dis Clin North Am. 2016;30(2):539–51. https://doi.org/10.1016/j.idc.2016.02.012.CrossRefPubMed

25.

Monsees E, Goldman J, Popejoy L. Staff nurses as antimicrobial stewards: an integrative literature review. Am J Infect Control. 2017;45(8):917–22. https://doi.org/10.1016/j.ajic.2017.03.009.CrossRefPubMed

26.

Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother. 2007;51(6):1967–71. https://doi.org/10.1128/AAC.01483-06.CrossRefPubMedPubMedCentral

27.

Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès J, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect. 2004;57(3):209–16. https://doi.org/10.1016/j.jhin.2004.03.022.CrossRefPubMed

28.

Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43–8. https://doi.org/10.1128/AAC.50.1.43-48.2006.CrossRefPubMedPubMedCentral

29.

Cuesta DP, Blanco VM, Vallejo ME, Hernández-Gómez C, Maya JJ, Motoa G, et al. Clinical impact of ertapenem de-escalation in critically-ill patients with Enterobacteriaceae infections. Rev Chilena Infectol. 2019;36(1):9–15. https://doi.org/10.4067/S0716-10182019000100009.CrossRefPubMed

30.

Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob Resist Infect Control. 2019;8(1):35. https://doi.org/10.1186/s13756-019-0471-0.CrossRefPubMedPubMedCentral

31.

Rohde JM, Jacobsen D, Rosenberg DJ. Role of the hospitalist in antimicrobial stewardship: a review of work completed and description of a multisite collaborative. Clin Ther. 2013;35(6):751–7. https://doi.org/10.1016/j.clinthera.2013.05.005.CrossRefPubMed

32.

Newland JG, Stach LM, De Lurgio SA, Hedican E, Yu D, Herigon JC, et al. Impact of a prospective-audit-with-feedback antimicrobial stewardship program at a children’s hospital. J Pediatric Infect Dis Soc. 2012;1(3):179–86. https://doi.org/10.1093/jpids/pis054.CrossRefPubMed

33.

Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348–55. https://doi.org/10.1093/ije/dyw098.CrossRefPubMed

Title: Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions
Authors: Christian Pallares
Cristhian Hernández-Gómez
Tobías Manuel Appel
Kevin Escandón
Sergio Reyes
Soraya Salcedo
Lorena Matta
Ernesto Martínez
Sara Cobo
Laura Mora
Adriana Marín
Adriana Correa
Elsa De La Cadena
Jesús Rodríguez-Baño
María Virginia Villegas
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Antibiotic
Piperacillin
Meropenem
Cefepime
Ertapenem
Vancomycin
Ceftriaxone
Published in: BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-022-07410-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Trends in hepatitis B notification rates in Guangzhou, China, between 2009 and 2020: an epidemiological study

Effect of a real-time automatic nosocomial infection surveillance system on hospital-acquired infection prevention and control

Signature of chronic hepatitis B virus infection in nails and hair

Factors affecting perforation of the esophagus in patients with deep neck infection

Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children

Lethal Waterhouse–Friderichsen syndrome caused by Capnocytophaga canimorsus in an asplenic patient

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page